EDIL3

Across TCGA pan-cancer cohorts, EDIL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EDIL3 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EDIL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EDIL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where EDIL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.937	0.982	.012	27	view →
LSCC	OS	Median	All	0.682	0.907	.004	15	view →
PDAC	DFS	Median	All	0.713	0.876	.004	12	view →
CCRCC	DFS	Median	III,IV	0.185	0.985	.014	11	view →
HNSC	OS	Tertile	III,IV	0.947	0.792	.012	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EDIL3–LUAD (OS)

Open the LUAD breakdown →